Deshpande Milind 4

What Happened
Milind Deshpande, a director of Spero Therapeutics (SPRO), was granted awards on June 23, 2026 totaling 30,000 shares. The filing shows a 10,000-share restricted stock unit (RSU) grant and a 20,000-share derivative award (an option-like grant). Both were reported as acquired at $0.00 per share (typical of compensation awards). These are grants, not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-23; Filing date: 2026-06-25 (appears timely under Form 4 rules).
• Grants: 10,000 RSUs (F1) and 20,000-share derivative/option award (F2); acquisition price $0.00.
• Vesting/Exercise: F1 — RSUs convert to one share per RSU and vest on June 23, 2027, subject to continued service. F2 — the shares underlying the option become exercisable in full on June 23, 2027, subject to continued service.
• Shares owned after the transaction: not specified in the provided excerpt — see the full Form 4 for total beneficial ownership.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax withholding, or late-filing flags were noted in the provided details.

Context
These awards are standard equity compensation for directors and are granted at no cash cost to align interests with shareholders. Because they vest contingent on continued service and were not purchased on the open market, they should not be read as an immediate buy signal; they reflect compensation rather than an outright insider purchase.